Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 4/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ADA | P00813 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228218 | 1.00 | NT5E (0.48) | NT5ELMNAHIF1AAHCYADORA2A | |
| SCHEMBL21078466 | 0.91 | AHCY (0.43) | NT5ELMNAHIF1AAHCYADORA2A | |
| SCHEMBL30138569 | 0.86 | ADORA2A (0.51) | AHCYADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL19859704 | 0.86 | ADORA2A (0.51) | AHCYADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL19859359 | 0.85 | ADORA2A (0.34) | NT5ELMNAHIF1AADORA2AADORA3 | |
| SCHEMBL31228262 | 0.82 | P2RY1 (0.47) | NT5ECA5A | |
| SCHEMBL15833211 | 0.82 | ADORA3 (0.48) | NT5EADORA3 | |
| SCHEMBL15833130 | 0.82 | ADORA3 (0.48) | NT5EADORA3 | |
| SCHEMBL16373866 | 0.81 | ADORA2A (0.36) | NT5EADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL19859343 | 0.80 | LMNA (0.60) | NT5ELMNAHIF1AAHCYADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | NT5E 13/4885LMNA 982/4885HIF1A 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.